Cash Flow Statement

Acquisitions Amortizatization of Intangibles Amortizatization of Intangibles Asset Writedowns and Impairment Asset Writedowns and Impairment Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Cash Change in Inventory Change in Inventory Change in Receivables Change in Receivables Depreciation & Amortization (CF)Depreciation & Amortization (CF)Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Sales of Property, Plant and Equipment Sales of Property, Plant and Equipment Share-based Compensation Share-based Compensation Shares Issued Shares Repurchased

Daily Values

Growth Metrics

Others

Accumulated Depreciation & Amortization Accumulated Depreciation & Amortization Cost of Revenue EBIAT Gross Profit Leases Long-Term Debt Repayments Machine, Furnitures, Fixtures & Other Other Gross PP&E Adjustments Other Gross PP&E Adjustments Property, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - Net Receivables - Other Shares Issued Shares Outstanding Shares Outstanding Shares Repurchased

Tonix Pharmaceuticals Holding (TNXP) Long-Term Debt Repayments (2024 - 2025)

Tonix Pharmaceuticals Holding has reported Long-Term Debt Repayments over the past 2 years, most recently at $50000.0 for Q2 2025.

Quarterly results put Long-Term Debt Repayments at $50000.0 for Q2 2025, down 92.91% from a year ago — trailing twelve months through Dec 2025 was $9.6 million (up 310.64% YoY), and the annual figure for FY2025 was $9.6 million, up 310.64%.
Long-Term Debt Repayments for Q2 2025 was $50000.0 at Tonix Pharmaceuticals Holding, down from $9.6 million in the prior quarter.
Over the last five years, Long-Term Debt Repayments for TNXP hit a ceiling of $9.6 million in Q1 2025 and a floor of $50000.0 in Q2 2025.